Finance

Lists
Why is SABS up २.३१%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
US$ ३.१०
+२.३१%
(+०.०७०) 1D
US$ ३.०९
-०.३३% (-०.०१०)
After hours
Closed: नोभेम्बर ९, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
US$ ३.१०
High
US$ ३.१८
Low
US$ ३.०५
Mkt. cap
२८.२१ करोड
Avg. vol.
६.४३ लाख
Volume
७.९० लाख
52-wk high
US$ ५.१५
52-wk low
US$ २.४४
EPS
-US$ ०.६३
Beta
०.६७
Shares outstanding
९.०१ करोड
No. of employees
८६
Open
US$ ३.१०
High
US$ ३.१८
Low
US$ ३.०५
Mkt. cap
२८.२१ करोड
Avg. vol.
६.४३ लाख
Volume
७.९० लाख
52-wk high
US$ ५.१५
52-wk low
US$ २.४४
EPS
-US$ ०.६३
Beta
०.६७
Shares outstanding
९.०१ करोड
No. of employees
८६
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees८६
Founded२०१४
HeadquartersMiami Beach, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current US$ ३.१०
US$ १५.०० (+३८३.८७%)
Average
US$ १३.२५ (+३२७.४२%)
Lowest
US$ ११.०० (+२५४.८४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$ १४.००
+३५१.६%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
US$ ११.००
+२५४.८%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ १५.००
+३८३.९%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
US$ १३.००
+३१९.४%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
US$ १०.००
+२२२.६%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
US$ १६.००
+४१६.१%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
US$ ६.००
+९३.५%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$ १४.००
+३५१.६%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
US$ ११.००
+२५४.८%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
US$ १५.००
+३८३.९%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
US$ १३.००
+३१९.४%
04/02/2026
Michael Yee
UBS
Buy
Maintained
US$ ७.००
+१२५.८%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
९७.२८ लाख
१.३४ करोड
१.६२ करोड
१.८१ करोड
Cost of revenue
९७.२८ लाख
१.३४ करोड
१.६२ करोड
१.८१ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६०.४२ लाख
६६.०० लाख
७२.०५ लाख
७८.२२ लाख
Operating expense
६०.४२ लाख
६६.०० लाख
७२.०५ लाख
७८.२२ लाख
Total operating expenses
१.५८ करोड
२.०० करोड
२.३४ करोड
२.५९ करोड
Operating income
-१.५८ करोड
-२.०० करोड
-२.३४ करोड
-२.५९ करोड
Other non operating income
-१७.२८ लाख
१.४४ लाख
-७.६१ लाख
१९.९१ लाख
EBT including unusual items
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
EBT excluding unusual items
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४१
-
-०.२८
-०.२६
Interest and investment income
७.०१ लाख
१०.४७ लाख
१७.०९ लाख
१६.०८ लाख
Interest expense
-६३.४६ हजार
-६२.७४ हजार
-६२.०० हजार
-
Net interest expenses
६.३७ लाख
९.८४ लाख
१६.४७ लाख
१६.०८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.५० करोड
-१.९२ करोड
-२.२५ करोड
-२.५१ करोड
Gain or loss from assets sale
-
-
-
-६६.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू